NASDAQ:ACXP Acurx Pharmaceuticals (ACXP) Stock Price, News & Analysis $2.28 +0.02 (+0.88%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.26▼$2.4050-Day Range$2.01▼$2.7952-Week Range$1.17▼$8.82Volume14,401 shsAverage Volume114,050 shsMarket Capitalization$36.12 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Acurx Pharmaceuticals alerts: Email Address Acurx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside426.3% Upside$12.00 Price TargetShort InterestHealthy4.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.28) to ($2.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.60 out of 5 starsMedical Sector498th out of 936 stocksPharmaceutical Preparations Industry229th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAcurx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcurx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Acurx Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.18% of the float of Acurx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcurx Pharmaceuticals has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Acurx Pharmaceuticals has recently decreased by 8.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcurx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcurx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACXP. Previous Next 3.2 News and Social Media Coverage News SentimentAcurx Pharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Acurx Pharmaceuticals this week, compared to 1 article on an average week.Search Interest6 people have searched for ACXP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders35.30% of the stock of Acurx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.53% of the stock of Acurx Pharmaceuticals is held by institutions.Read more about Acurx Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Acurx Pharmaceuticals are expected to decrease in the coming year, from ($1.28) to ($2.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acurx Pharmaceuticals is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acurx Pharmaceuticals is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcurx Pharmaceuticals has a P/B Ratio of 6.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Acurx Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...Click here to see how >>> About Acurx Pharmaceuticals Stock (NASDAQ:ACXP)Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Read More ACXP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACXP Stock News HeadlinesJuly 17, 2024 | prnewswire.comUSPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut MicrobiomeJuly 17, 2024 | americanbankingnews.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Significant Decline in Short InterestJuly 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” July 16, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business UpdateJuly 15, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific ConferenceMay 17, 2024 | seekingalpha.comAcurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call TranscriptMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Acurx Pharmaceuticals Amid Promising CDI Drug Candidate Progress and Solid FinancialsMay 16, 2024 | insidermonkey.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2024 Earnings Call TranscriptJuly 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” May 16, 2024 | finance.yahoo.comAcurx Pharmaceuticals Inc (ACXP) Q1 2024 Earnings Call Transcript Highlights: Key Financial and ...May 16, 2024 | finance.yahoo.comQ1 2024 Acurx Pharmaceuticals Inc Earnings CallMay 15, 2024 | morningstar.comAcurx Pharmaceuticals Inc Ordinary SharesMay 15, 2024 | msn.comAcurx Pharmaceuticals GAAP EPS of -$0.28 misses by $0.04May 15, 2024 | prnewswire.comAcurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile InfectionMay 15, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business UpdateMay 2, 2024 | finance.yahoo.comAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific ConferenceMay 2, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific ConferenceApril 25, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific ConferenceSee More Headlines Receive ACXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Confirmed)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACXP CUSIPN/A CIK1736243 Webwww.acurxpharma.com Phone917-533-1469FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+426.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-308.46% Return on Assets-193.34% Debt Debt-to-Equity RatioN/A Current Ratio2.93 Quick Ratio2.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book6.71Miscellaneous Outstanding Shares15,843,000Free Float10,250,000Market Cap$36.12 million OptionableOptionable Beta-1.72 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Robert J. DeLuccia (Age 78)Co-Founder & Executive Chairman Comp: $701.54kMr. David P. Luci CPA (Age 57)Esq., J.D., Co-Founder, President, CEO, Corporate Secretary & Director Comp: $668.98kMr. Robert G. Shawah CPA (Age 57)CPA, Co-Founder & CFO Comp: $470.29kKey CompetitorsIndaptus TherapeuticsNASDAQ:INDPAytu BioPharmaNASDAQ:AYTUVeruNASDAQ:VERUIncannex HealthcareNASDAQ:IXHLCorvus PharmaceuticalsNASDAQ:CRVSView All CompetitorsInstitutional OwnershipProspect Financial Services LLCBought 5,250 shares on 7/15/2024Ownership: 1.756%View All Institutional Transactions ACXP Stock Analysis - Frequently Asked Questions How have ACXP shares performed this year? Acurx Pharmaceuticals' stock was trading at $3.83 at the beginning of 2024. Since then, ACXP stock has decreased by 40.5% and is now trading at $2.28. View the best growth stocks for 2024 here. How were Acurx Pharmaceuticals' earnings last quarter? Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) posted its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.04. When did Acurx Pharmaceuticals IPO? Acurx Pharmaceuticals (ACXP) raised $15 million in an IPO on Friday, June 25th 2021. The company issued 2,500,000 shares at $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities served as the underwriters for the IPO. Who are Acurx Pharmaceuticals' major shareholders? Acurx Pharmaceuticals' top institutional shareholders include Prospect Financial Services LLC (1.76%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Carl Sailer, David P Luci and Robert J Deluccia. View institutional ownership trends. How do I buy shares of Acurx Pharmaceuticals? Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACXP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.